Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026)
Neumora Therapeutics' (NMRA) quarterly Income from Continuing Operations came in at 53458000.0 in Q1 2026, up 21.38% year-on-year from 44043287.4 in Q1 2025, and up 10.01% quarter-over-quarter from 59402000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 53458000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 21.38% year-over-year to 53458000.0 in Q1 2026; TTM through Mar 2026 was 222346000.0, a 13.84% increase from a year earlier, with the FY2025 full-year figure at 236880000.0, up 2.83% from the prior year.
- Income from Continuing Operations improved to 53458000.0 in Q1 2026 per NMRA's latest filing, from 59402000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 30886000.0 in Q3 2022 and bottomed at 171895000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 56755000.0 (2025), against an average of 65041400.0.
- Across the five-year window, Income from Continuing Operations plunged 71.69% in 2023 and jumped 45.78% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 171895000.0 in 2022, then jumped by 36.9% to 108462000.0 in 2023, then surged by 45.78% to 58810000.0 in 2024, then fell by 1.01% to 59402000.0 in 2025, then increased by 10.01% to 53458000.0 in 2026.
- Per Business Quant, the three latest NMRA Income from Continuing Operations figures stand at 53458000.0 (Q1 2026), 59402000.0 (Q4 2025), and 56755000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Neumora Therapeutics | 280.60 Mn | 280.60 Mn | - | -53.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.46 Mn |
| Dec 31, 2025 | -59.40 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.73 Mn |
| Mar 31, 2025 | -67.99 Mn |
| Dec 31, 2024 | -58.81 Mn |
| Sep 30, 2024 | -72.55 Mn |
| Jun 30, 2024 | -58.70 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.46 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -38.69 Mn |
| Dec 31, 2022 | -171.90 Mn |
| Sep 30, 2022 | -30.89 Mn |